Header Logo

Connection

Robin Jones to Male

Back to Details
This is a "connection" page, showing publications Robin Jones has written about Male.
Robin Jones
Connection Strength
2.164
Male
  1. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 05 01; 8(5):740-747.
    View in: PubMed
    Score: 0.061
  2. Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Med. 2021 06; 10(11):3565-3574.
    View in: PubMed
    Score: 0.057
  3. Current Reality of Treating Advanced Soft Tissue Sarcoma as Illustrated by Case Studies. Oncology. 2021; 99 Suppl 1:8-16.
    View in: PubMed
    Score: 0.057
  4. Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. Clin Cancer Res. 2021 07 15; 27(14):3861-3866.
    View in: PubMed
    Score: 0.056
  5. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021 03; 145:132-142.
    View in: PubMed
    Score: 0.056
  6. Future Directions in the Treatment of Osteosarcoma. Cells. 2021 01 15; 10(1).
    View in: PubMed
    Score: 0.056
  7. Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. Anticancer Res. 2020 Dec; 40(12):7003-7007.
    View in: PubMed
    Score: 0.055
  8. Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. Mol Cancer Ther. 2021 01; 20(1):132-141.
    View in: PubMed
    Score: 0.055
  9. Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open. 2020 08; 5(4).
    View in: PubMed
    Score: 0.054
  10. Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers. JCO Glob Oncol. 2020 07; 6:1046-1051.
    View in: PubMed
    Score: 0.054
  11. Low-grade Fibromyxoid Sarcoma: Treatment Outcomes and Efficacy of Chemotherapy. In Vivo. 2020 Jan-Feb; 34(1):239-245.
    View in: PubMed
    Score: 0.052
  12. Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy. Med Oncol. 2019 Dec 27; 37(2):13.
    View in: PubMed
    Score: 0.052
  13. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. Eur J Cancer. 2019 10; 120:132-139.
    View in: PubMed
    Score: 0.051
  14. Sarcomas and old age: few options for such a large patient population. Future Oncol. 2019 Sep; 15(26s):11-15.
    View in: PubMed
    Score: 0.051
  15. Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer. 2019 Dec 15; 125(24):4435-4441.
    View in: PubMed
    Score: 0.051
  16. The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma. Anticancer Res. 2019 Sep; 39(9):4891-4896.
    View in: PubMed
    Score: 0.051
  17. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. Cancer. 2019 07 15; 125(14):2445-2454.
    View in: PubMed
    Score: 0.050
  18. Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients. Anticancer Res. 2019 Jan; 39(1):347-351.
    View in: PubMed
    Score: 0.049
  19. Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas. Expert Rev Anticancer Ther. 2018 12; 18(12):1241-1248.
    View in: PubMed
    Score: 0.048
  20. Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. Med Oncol. 2018 Sep 05; 35(11):138.
    View in: PubMed
    Score: 0.047
  21. Synovial Sarcoma of the Thyroid Gland, Diagnostic Pitfalls and Clinical Management. Anticancer Res. 2018 Sep; 38(9):5275-5282.
    View in: PubMed
    Score: 0.047
  22. Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Med Oncol. 2018 Aug 20; 35(10):131.
    View in: PubMed
    Score: 0.047
  23. Clear Cell Sarcoma-like Tumor of the Gastrointestinal Tract: Clinical Outcome and Pathologic Features of a Molecularly Characterized Tertiary Center Case Series. Anticancer Res. 2018 03; 38(3):1479-1483.
    View in: PubMed
    Score: 0.046
  24. Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. Am J Clin Oncol. 2018 02; 41(2):147-151.
    View in: PubMed
    Score: 0.046
  25. Dear John Hunter. BMJ. 2016 12 14; 355:i6515.
    View in: PubMed
    Score: 0.042
  26. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Oct; 76(4):777-84.
    View in: PubMed
    Score: 0.038
  27. Redefining the standard of care in metastatic leiomyosarcoma. Lancet Oncol. 2015 Apr; 16(4):360-2.
    View in: PubMed
    Score: 0.037
  28. Analysis of clinical prognostic factors for adult patients with head and neck sarcomas. Otolaryngol Head Neck Surg. 2014 Dec; 151(6):976-83.
    View in: PubMed
    Score: 0.036
  29. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin Cancer Res. 2015 Feb 15; 21(4):693-700.
    View in: PubMed
    Score: 0.036
  30. A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors. Invest New Drugs. 2014 Feb; 32(1):171-7.
    View in: PubMed
    Score: 0.034
  31. Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol. 2012 Aug; 35(4):351-7.
    View in: PubMed
    Score: 0.031
  32. Chemotherapy in clear cell sarcoma. Med Oncol. 2011 Sep; 28(3):859-63.
    View in: PubMed
    Score: 0.029
  33. Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. Cancer Chemother Pharmacol. 2011 Aug; 68(2):423-9.
    View in: PubMed
    Score: 0.028
  34. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005 Dec; 41(18):2853-60.
    View in: PubMed
    Score: 0.020
  35. Oncological Outcome After Diagnostic Biopsies in Gastrointestinal Stromal Tumors: A Retrospective Cohort Study. Ann Surg. 2021 12 01; 274(6):e1093-e1098.
    View in: PubMed
    Score: 0.015
  36. Treatments and Outcomes in Oligometastatic Soft Tissue Soft Sarcoma - A Single Centre Retrospective Analysis. Anticancer Res. 2021 Oct; 41(10):5089-5096.
    View in: PubMed
    Score: 0.015
  37. Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma. Future Oncol. 2021 Sep; 17(27):3627-3636.
    View in: PubMed
    Score: 0.015
  38. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. Eur J Cancer. 2021 09; 155:236-244.
    View in: PubMed
    Score: 0.015
  39. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 10 01; 39(28):3128-3139.
    View in: PubMed
    Score: 0.015
  40. CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes. J Immunother Cancer. 2021 08; 9(8).
    View in: PubMed
    Score: 0.015
  41. Gastrointestinal leiomyosarcoma demonstrate a predilection for distant recurrence and poor response to systemic treatments. Eur J Surg Oncol. 2021 10; 47(10):2595-2601.
    View in: PubMed
    Score: 0.014
  42. Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Future Oncol. 2021 Aug; 17(22):2923-2939.
    View in: PubMed
    Score: 0.014
  43. Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. Eur J Surg Oncol. 2021 08; 47(8):2173-2181.
    View in: PubMed
    Score: 0.014
  44. Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. Cancer Med. 2021 04; 10(8):2645-2659.
    View in: PubMed
    Score: 0.014
  45. Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial. JAMA Oncol. 2020 Nov 01; 6(11):1778-1782.
    View in: PubMed
    Score: 0.014
  46. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 11; 21(11):1423-1432.
    View in: PubMed
    Score: 0.014
  47. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. J Clin Oncol. 2020 10 01; 38(28):3294-3303.
    View in: PubMed
    Score: 0.014
  48. SMARCA4-Deficient Thoracic Sarcoma. Int J Surg Pathol. 2021 Sep; 29(6):640-641.
    View in: PubMed
    Score: 0.013
  49. Superficial CD34-Positive Fibroblastic Tumor. Int J Surg Pathol. 2020 Dec; 28(8):879-881.
    View in: PubMed
    Score: 0.013
  50. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020 07; 21(7):935-946.
    View in: PubMed
    Score: 0.013
  51. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 07; 21(7):923-934.
    View in: PubMed
    Score: 0.013
  52. Metastatic Soft Tissue Sarcomas in Adolescents and Young Adults: A Specialist Center Experience. J Adolesc Young Adult Oncol. 2020 12; 9(6):628-638.
    View in: PubMed
    Score: 0.013
  53. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. JAMA. 2020 04 07; 323(13):1266-1276.
    View in: PubMed
    Score: 0.013
  54. Rib destruction by epithelioid tumour in a young man. J Clin Pathol. 2020 Oct; 73(10):e2.
    View in: PubMed
    Score: 0.013
  55. Primary iliocaval leiomyosarcomas: The path beyond surgery. Eur J Surg Oncol. 2020 05; 46(5):893-897.
    View in: PubMed
    Score: 0.013
  56. Imaging Soft-tissue Sarcomas of the Head and Neck: A Tertiary Soft-tissue Sarcoma Unit Experience. Anticancer Res. 2019 Nov; 39(11):6223-6230.
    View in: PubMed
    Score: 0.013
  57. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2020 01 01; 126(1):98-104.
    View in: PubMed
    Score: 0.013
  58. Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance. Ann Surg Oncol. 2019 Dec; 26(13):4699-4706.
    View in: PubMed
    Score: 0.013
  59. First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clin Cancer Res. 2019 10 01; 25(19):5808-5817.
    View in: PubMed
    Score: 0.013
  60. Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). Clin Cancer Res. 2019 09 01; 25(17):5295-5300.
    View in: PubMed
    Score: 0.013
  61. Systemic Interferon-? Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial. Cancer Immunol Res. 2019 08; 7(8):1237-1243.
    View in: PubMed
    Score: 0.013
  62. Age-related sarcoma patient experience: results from a national survey in England. BMC Cancer. 2018 Oct 17; 18(1):991.
    View in: PubMed
    Score: 0.012
  63. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. JAMA Oncol. 2018 09 01; 4(9):e180219.
    View in: PubMed
    Score: 0.012
  64. Desmoid fibromatosis through the patients' eyes: time to change the focus and organisation of care? Support Care Cancer. 2019 Mar; 27(3):965-980.
    View in: PubMed
    Score: 0.012
  65. Pancreaticoduodenectomy for the Management of Pancreatic or Duodenal Metastases from Primary Sarcoma. Anticancer Res. 2018 Jul; 38(7):4041-4046.
    View in: PubMed
    Score: 0.012
  66. Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas. AJR Am J Roentgenol. 2018 Jan; 210(1):175-182.
    View in: PubMed
    Score: 0.011
  67. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. J Clin Oncol. 2017 Oct 20; 35(30):3433-3439.
    View in: PubMed
    Score: 0.011
  68. Desmoplastic small round cell tumor: evaluation of reverse transcription-polymerase chain reaction and fluorescence in situ hybridization as ancillary molecular diagnostic techniques. Virchows Arch. 2017 Nov; 471(5):631-640.
    View in: PubMed
    Score: 0.011
  69. The Adequacy of Core Biopsy in the Assessment of Smooth Muscle Neoplasms of Soft Tissues: Implications for Treatment and Prognosis. Am J Surg Pathol. 2017 Jul; 41(7):923-931.
    View in: PubMed
    Score: 0.011
  70. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017 08; 18(8):1089-1103.
    View in: PubMed
    Score: 0.011
  71. Pazopanib, a promising option for the treatment of aggressive fibromatosis. Anticancer Drugs. 2017 04; 28(4):421-426.
    View in: PubMed
    Score: 0.011
  72. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. J Clin Oncol. 2016 11 10; 34(32):3898-3905.
    View in: PubMed
    Score: 0.010
  73. Desmoplastic Small Round Cell Tumor: Pathology, Genetics, and Potential Therapeutic Strategies. Int J Surg Pathol. 2016 Dec; 24(8):672-684.
    View in: PubMed
    Score: 0.010
  74. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30; 388(10043):488-97.
    View in: PubMed
    Score: 0.010
  75. p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib? Cancer Biol Ther. 2016 05 03; 17(5):543-5.
    View in: PubMed
    Score: 0.010
  76. Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study. Anticancer Res. 2015 Nov; 35(11):6213-7.
    View in: PubMed
    Score: 0.010
  77. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10; 34(8):786-93.
    View in: PubMed
    Score: 0.010
  78. Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res. 2013 Dec 15; 19(24):6902-11.
    View in: PubMed
    Score: 0.008
  79. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One. 2012; 7(2):e32165.
    View in: PubMed
    Score: 0.008
  80. Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour. Acta Oncol. 2012 Apr; 51(4):550-4.
    View in: PubMed
    Score: 0.007
  81. Advanced aggressive fibromatosis: Effective palliation with chemotherapy. Acta Oncol. 2011 Apr; 50(3):455-61.
    View in: PubMed
    Score: 0.007
  82. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009 Nov; 45(17):2930-4.
    View in: PubMed
    Score: 0.006
  83. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007 Jul; 8(7):595-602.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.